SOPHiA GENETICS (NASDAQ:SOPH) President Ross Muken Sells 4,442 Shares

Key Points

• Ross Muken sold 4,442 shares of SOPHiA GENETICS on April 13 at an average price of $4.76 under a pre-arranged Rule 10b5-1 trading plan to cover tax withholding, reducing his ownership by 0.64% to 685,232 shares (≈$3.26M).
• The stock traded up about 2.3% to $4.96, has a market cap of roughly $339.7M and a 52‑week range of $2.58–$5.70, while the company reported a loss (EPS -$0.28) and negative margins in its most recent quarter.
• Analyst sentiment is mixed but skewed toward higher targets—average price target $7.00 with two Buys and one Sell—and institutional ownership is around 31.6% with several funds taking small positions recently.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) President Ross Muken sold 4,442 shares of SOPHiA GENETICS stock in a transaction on Monday, April 13th. The shares were sold at an average price of $4.76, for a total transaction of $21,143.92. Following the completion of the sale, the president directly owned 685,232 shares of the company's stock, valued at approximately $3,261,704.32. This trade represents a 0.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ross Muken also recently made the following trade(s):

• On Friday, April 10th, Ross Muken sold 3,687 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.69, for a total transaction of $17,292.03.
• On Thursday, April 9th, Ross Muken sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total transaction of $9,243.00.
• On Wednesday, April 8th, Ross Muken sold 2,786 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total transaction of $13,484.24.
• On Tuesday, April 7th, Ross Muken sold 2,424 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total transaction of $11,804.88.
• On Thursday, March 19th, Ross Muken sold 1,183 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total transaction of $5,666.57.

SOPHiA GENETICS Stock Up 2.3%

SOPH traded up $0.11 during midday trading on Tuesday, hitting $4.96. The company had a trading volume of 148,768 shares, compared to its average volume of 183,135. SOPHiA GENETICS SA has a 52 week low of $2.58 and a 52 week high of $5.70. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. The company has a market capitalization of $339.71 million, a price-to-earnings ratio of -9.73 and a beta of 1.04. The stock's 50 day moving average price is $4.74 and its 200 day moving average price is $4.71.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.08). SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. The company had revenue of $21.71 million during the quarter, compared to the consensus estimate of $21.20 million. On average, research analysts anticipate that SOPHiA GENETICS SA will post -0.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Guggenheim lifted their price target on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a "buy" rating in a research note on Monday, January 26th. Weiss Ratings reissued a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Finally, BTIG Research reissued a "buy" rating and set a $7.00 target price on shares of SOPHiA GENETICS in a research report on Tuesday, March 3rd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, SOPHiA GENETICS currently has an average rating of "Hold" and an average target price of $7.00.

Institutional Investors Weigh In On SOPHiA GENETICS

Hedge funds and other institutional investors have recently made changes to their positions in the business. Savvy Advisors Inc. bought a new stake in shares of SOPHiA GENETICS during the third quarter worth about $48,000. Squarepoint Ops LLC bought a new stake in shares of SOPHiA GENETICS during the third quarter worth about $49,000. Perkins Capital Management Inc. bought a new stake in shares of SOPHiA GENETICS during the fourth quarter worth about $49,000. Quadrature Capital Ltd bought a new stake in shares of SOPHiA GENETICS during the fourth quarter worth about $54,000. Finally, XTX Topco Ltd bought a new stake in shares of SOPHiA GENETICS during the fourth quarter worth about $55,000. 31.59% of the stock is owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.